Open AccessVedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety
Author(s) -
Britt Christensen,
Ruben J. Colman,
Dejan Micić,
Peter G. Gibson,
Sarah R. Goeppinger,
Andrés Yarur,
Christopher R. Weber,
Russell D. Cohen,
David T. Rubin
Publication year - 2018
Publication title -
inflammatory bowel diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.932
H-Index - 146
eISSN - 1536-4844
pISSN - 1078-0998
DOI - 10.1093/ibd/izx067
Subject(s) - vedolizumab , inflammatory bowel disease , medicine , ulcerative colitis , crohn's disease , gastroenterology , disease , inflammatory bowel diseases , maintenance therapy , chemotherapy
Vedolizumab is approved for moderate to severe Crohn's disease (CD) and ulcerative colitis (UC). We present prospective, 1-year data of the real-world effectiveness and safety of vedolizumab in inflammatory bowel disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom